摘要
目的探讨中晚期食管癌患者循环外泌体miR-20a和HER-2蛋白表达与同步放化疗疗效的关系。方法选择2016年7月至2018年4月期间在皖南医学院第一附属医院接受治疗的67例初诊中晚期食管癌患者,行常规同步放化疗。采用实时荧光定量PCR(QPCR)检测外周血外泌体中miR-20a的表达,采用免疫组化SP法检测活检组织中HER-2蛋白的表达量。分析两者表达与食管癌临床病理特征的关系。绘制受试者工作特征(ROC)曲线评价miR-20a预测疗效的效能。采用双荧光素酶报告基因实验验证miR-20a与HER-2的靶向关系。结果食管癌患者循环外泌体miR-20a表达水平为1.07±0.40,其中32例患者miR-20a高表达,35例低表达;37例HER-2蛋白阳性,30例阴性。循环外泌体miR-20a表达仅与肿瘤直径、分化程度、临床分期有关(P<0.05),HER-2表达与临床病理特征均无关(P>0.05)。治疗有效组(n=44)患者循环外泌体miR-20a高表达率和组织HER-2阳性表达率明显低于治疗无效组(n=23)患者,差异有统计学意义(P<0.05)。循环外泌体miR-20a预测中晚期食管癌患者同步放化疗疗效的ROC曲线下面积为0.700(95%CI:0.567~0.833,P=0.007)。截断值为1.205。双荧光素酶报告基因实验证实,HER-2与miR-20a存在靶向关系。结论中晚期食管癌患者循环外泌体miR-20a调控HER-2表达,有望成为预测同步放化疗敏感性的辅助指标。
Objective To investigate the relationship between the expression of miR-20a in exocrine bodies and HER-2 protein of patients with advanced esophageal cancer and the effect of concurrent radiotherapy and chemotherapy.Methods From July 2016 to April 2018,67 newly diagnosed patients with advanced esophageal cancer who were treated in the First Affiliated Hospital of Wannan Medical College were selected for routine concurrent radiotherapy and chemotherapy.The expression of miR-20a was detected by real-time fluorescence quantitative PCR(QPCR),and the expression of HER-2 protein in biopsy tissue was detected by SP immunohistochemistry.The relationship between their expression and the clinicopathological characteristics of esophageal cancer was analyzed.ROC curve was used to evaluate the efficacy of miR-20a in predicting efficacy.The targeting relationship between miR-20a and HER-2 was verified by double luciferase reporter gene experiment.Results The expression of miR-20a was 1.07±0.40 in exocrine body of esophageal cancer patients,of which 32 patients had high expression of miR-20a,35 patients had low expression of miR-20a;37 patients had positive expression of HER-2 protein,30 patients had negative expression of HER-2 protein.The expression of miR-20a was only related to tumor diameter,differentiation degree and clinical stage(P<0.05).HER-2 expression was not correlated with clinicopathological features(P>0.05).The high expression rate of miR-20a and the positive expression rate of HER-2 in the effective group(n=44)were significantly lower than those in the ineffective group(n=23),the difference was statistically significant(P<0.05).The area under the ROC curve of circulating exosome miR-20a was 0.700(95%CI:0.567-0.833,P=0.007)for predicting the efficacy of concurrent chemoradiotherapy in patients with advanced esophageal cancer.The double luciferase reporter gene assay confirmed the targeting relationship between HER-2 and miR-20a.Conclusion Circulating exosome miR-20a regulates the expression of HER-2 in patients
作者
薛良军
冯艳
汪楠
XUE Liangjun;FENG Yan;WANG Nan(Department of Radiotherapy,the First Affiliated Hospital of Wannan Medical College,Wuhu 241001,China)
出处
《临床肿瘤学杂志》
CAS
北大核心
2019年第12期1099-1103,共5页
Chinese Clinical Oncology
关键词
中晚期食管癌
miR-20a
同步放化疗
HER-2
Advanced esophageal squamous cell carcinoma
miR-20a
Concurrent chemoradiotherapy
HER-2
